RBC Capital analyst Douglas Miehm raised the firm’s price target on Bausch Health to $9 from $8 and keeps a Sector Perform rating on the shares ahead of its Q2 results. Investor focus will likely fall on Xifaxan growth, the potential timeline for distribution of Bausch + Lomb shares to Bausch Health shareholders, and the timing of the finalization of the IRS settlement related to the Granite Trust situation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BHC: